Fu Shunjun, Guo Zhiyong, Li Shaoqiang, Kuang Ming, Hu Wenjie, Hua Yunpeng, He Xiaoshun, Peng Baogang
Organ Transplant Center, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, 510080, People's Republic of China.
Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine (Guangdong Provincial Hospital of TCM), Guangzhou, 510120, People's Republic of China.
Tumour Biol. 2016 Mar;37(3):3433-40. doi: 10.1007/s13277-015-4136-1. Epub 2015 Oct 8.
Gamma-glutamyltranspeptidase (γ-GGT), an oxidative stress marker, is correlated with inflammation in the extracellular hepatic microenvironment. This study aimed to evaluate the prognostic value of serum γ-GGT levels in patients with hepatocellular carcinoma (HCC) after hepatectomy. Three hundred and eight patients who underwent hepatic resection for HCC were included in the study. Preoperative serum γ-GGT levels, as well as demographic, clinical, and pathologic data, were analyzed. The optimal cutoff value of γ-GGT was 88 U/L. All patients were divided into γ-GGT ≤ 88 U/L group (n = 146) and γ-GGT > 88 U/L group (n = 162). The disease-free survival (DFS) and overall survival (OS) rates of patients in the γ-GGT > 88 U/L group were poorer than those in γ-GGT ≤ 88 U/L group. Preoperative serum γ-GGT levels, associating with gender, HBsAg status, tumor size, capsulation, tumor number, and vascular invasion, was an independent prognostic predictor of disease-free survival [hazard ratio (HR) = 1.616; 95 % confidence interval (CI), 1.223-2.135; P = 0.001] and overall survival (HR = 2.043; 95 % CI, 1.509-2.766; P < 0.001). Furthermore, γ-GGT was also associated with DFS and OS in small HCC (tumor size ≤5 cm) and alpha-fetoprotein (AFP) ≤ 200 ng/mL subgroup. In conclusion, γ-GGT is a promising and reliable prognostic biomarker in HCC patients after hepatic resection, especially for patients with small HCC or AFP ≤ 200 ng/mL.
γ-谷氨酰转肽酶(γ-GGT)作为一种氧化应激标志物,与肝细胞外微环境中的炎症相关。本研究旨在评估血清γ-GGT水平对肝细胞癌(HCC)患者肝切除术后的预后价值。本研究纳入了308例行肝癌肝切除术的患者。分析了术前血清γ-GGT水平以及人口统计学、临床和病理数据。γ-GGT的最佳临界值为88 U/L。所有患者分为γ-GGT≤88 U/L组(n = 146)和γ-GGT>88 U/L组(n = 162)。γ-GGT>88 U/L组患者的无病生存期(DFS)和总生存期(OS)率低于γ-GGT≤88 U/L组。术前血清γ-GGT水平与性别、HBsAg状态、肿瘤大小、包膜、肿瘤数量和血管侵犯相关,是无病生存期的独立预后预测指标[风险比(HR)= 1.616;95%置信区间(CI),1.223 - 2.135;P = 0.001]和总生存期(HR = 2.043;95% CI,1.509 - 2.766;P < 0.001)。此外,γ-GGT在小肝癌(肿瘤大小≤5 cm)和甲胎蛋白(AFP)≤200 ng/mL亚组中也与DFS和OS相关。总之,γ-GGT是肝癌患者肝切除术后一个有前景且可靠的预后生物标志物,尤其对于小肝癌或AFP≤200 ng/mL的患者。